Last reviewed 2026-05-14 · How we verify

Elinzanetant (BAY3427080)

Elinzanetant (BAY3427080) is a NK3 receptor antagonist Small molecule drug developed by Bayer. It is currently in Phase 3 development for Vasomotor symptoms (hot flashes and night sweats) associated with menopause. Also known as: NT-814.

Elinzanetant is a neurokinin-3 (NK3) receptor antagonist that reduces vasomotor symptoms by blocking neurokinin signaling in the hypothalamus.

Elinzanetant is a neurokinin-3 (NK3) receptor antagonist that reduces vasomotor symptoms by blocking neurokinin signaling in the hypothalamus. Used for Vasomotor symptoms (hot flashes and night sweats) associated with menopause.

At a glance

Mechanism of action

The drug selectively antagonizes the NK3 receptor, which plays a key role in thermoregulation and the pathophysiology of hot flashes and night sweats. By blocking NK3 receptor signaling in the central nervous system, elinzanetant suppresses the neuronal circuits responsible for vasomotor instability associated with menopause. This mechanism offers a non-hormonal approach to managing menopausal symptoms.

Approved indications

• Vasomotor symptoms (hot flashes and night sweats) associated with menopause

Common side effects

• Headache
• Nausea
• Dizziness
• Fatigue

Key clinical trials

• A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (PHASE3)
• A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2) (PHASE3)
• A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer (PHASE3)
• A Study to Investigate Relative Bioavailability, Safety and Tolerability of Single- and Multiple-doses of Elinzanetant in Healthy Female Participants (PHASE1)
• A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause (PHASE3)
• A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally (PHASE1)
• A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women (PHASE1)
• A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Elinzanetant (BAY3427080) CI brief — competitive landscape report
• Elinzanetant (BAY3427080) updates RSS · CI watch RSS
• Bayer portfolio CI

Frequently asked questions about Elinzanetant (BAY3427080)

Related

• Drug class: All NK3 receptor antagonist drugs
• Target: All drugs targeting NK3 receptor (neurokinin-3 receptor)
• Manufacturer: Bayer — full pipeline
• Therapeutic area: All drugs in Women's Health / Endocrinology
• Indication: Drugs for Vasomotor symptoms (hot flashes and night sweats) associated with menopause
• Also known as: NT-814
• Compare: Elinzanetant (BAY3427080) vs similar drugs
• Pricing: Elinzanetant (BAY3427080) cost, discount & access